International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announced on Wednesday that it has secured a significant enterprise imaging contract with UZ Leuven, Belgium's largest university hospital. This agreement allows UZ Leuven to implement Sectra's digital pathology module, streamlining primary diagnostics for pathologists and improving efficiency for both clinicians and patients in cancer care.
Recognised as the best hospital in Belgium by Newsweek and ranked among the top 50 globally, UZ Leuven stands out as a major healthcare provider in the region. The 10-year contract, part of Sectra's fiscal year 2024/2025, reflects a commitment to advancing diagnostic capabilities.
Sectra's digital pathology solution is integrated within its broader enterprise imaging framework, promoting a unified approach to imaging while optimising operational costs. The scalable system, centred around a Vendor Neutral Archive (VNA), facilitates growth across various medical specialities and institutions.
Founded in 1978 and headquartered in Linköping, Sweden, Sectra is dedicated to enhancing healthcare efficiency globally. In the 2023/2024 fiscal year, the company reported sales of SEK2,964m.
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
GlycoMimetics to combine with Crescent Biopharma
MilliporeSigma expands ADC manufacturing capacity
Merck and Moderna launch new Phase 3 trial for cancer vaccine
RaySearch Laboratories AB names new CFO
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
Elicera Therapeutics completes patient enrolment for phase I/II trial of cancer therapy ELC-100
Repare Therapeutics reports positive safety and tolerability data from Phase 1 MYTHIC trial